Adrian M. Senderowicz, MD; Ellen Vitetta, PhD; Donna Headlee, RN; Victor Ghetie, PhD; Jonathan W. Uhr, MD; William D. Figg, PharmD; Richard M. Lush, PhD; Maryalice Stetler-Stevenson, MD, PhD; Glenn Kershaw, MD; Douglas W. Kingma, MD; Elaine S. Jaffe, MD; Edward A. Sausville, MD, PhD
Senderowicz A., Vitetta E., Headlee D., Ghetie V., Uhr J., Figg W., Lush R., Stetler-Stevenson M., Kershaw G., Kingma D., Jaffe E., Sausville E.; Complete Sustained Response of a Refractory, Post-Transplantation, Large B-Cell Lymphoma to an Anti-CD22 Immunotoxin. Ann Intern Med. 1997;126:882-885. doi: 10.7326/0003-4819-126-11-199706010-00005
Download citation file:
Published: Ann Intern Med. 1997;126(11):882-885.
CD19, CD20, CD21, CD22: B-cell surface markers frequently expressed on the surface of B-cell tumors. The immunotoxin used in our patient is directed against CD22.
EBER-1: Epstein-Barr encoded RNA.
Immunotoxin: A drug formed by chemical linkage of an antibody to a toxin.
RFB4-dgA: The immunotoxin used in our patient; it consists of the murine monoclonal antibody RFB4, which is linked to the deglycosylated A-chain of ricin, a plant toxin.
Vascular leak syndrome: A side effect of immunotoxin treatment that consists of nontargeted damage to endothelial cells and manifests as hypoalbuminemia and edema in its mild form.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only